How well will the world respond next time—especially if that virus has a 5 percent fatality rate rather than the ~1 percent of COVID-19?
CGD Policy Blogs
We welcome Biden’s announcement last week that the US will purchase 500 million COVID-19 vaccine doses for distribution to lower income countries. And while no single country is responsible for vaccinating the world, there is one global institution that could be doing more.
Dear President Biden and Congress: Time for US to Lead Response to the Growing COVID-19 Global Vaccine Crisis
Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and safe vaccines, support rapid vaccine distribution and administration, and build a sustainable global network of vaccine manufacturing capacity. Vaccines offer an exit route out of the pandemic – but only if they reach a critical mass of people in need across continents, socioeconomic strata, and marginalized populations.
In 2003, an estimated 3 million people died of HIV/AIDS globally. In May of that year, galvanized by the growing number of preventable deaths given the availability of an effective medicine, the President’s Emergency Plan for AIDS Relief—PEPFAR—was signed into law.
India’s second COVID-19 wave has been explosive, reaching world record totals of over 300,000 daily officially reported cases. The true number is likely to be much higher, with a large number of cases missed as indicated by the delays in testing and rapidly rising positivity rates - currently one in every four people tested are positive for COVID-19 across India. Leading models estimate that there could be over 1 million cases per day. The health service has collapsed, with queues of ambulances parked outside full hospitals, oxygen and drug shortages in multiple states, and life-saving non-COVID services interrupted.
Enough. We cannot continue business as usual. Until this crisis is over—and over everywhere—exiting the COVID-19 mass casualty event must be the singular focus of the international community.
What's behind the limited demand for multilateral development bank financing for vaccine procurement and vaccination so far? Amanda Glassman reviews 5 possibilities.
COVID-19 Vaccination and the Multilateral Development Banks: Moving Towards a More Systematic and Strategic Approach
How should the MDB vaccine effort intersect with global efforts like COVAX, or indeed plans to share or donate vaccine amongst countries? In this blog, we look at two issues raised by the World Bank’s approach so far and offer options for a better way forward.
This week, the Inter-American Development Bank’s governors gather for their annual meeting. Much is at stake as the region reels under the compound crises of COVID-19 and recession. But none of this urgency is yet evident in the IDB’s public case to its member countries.
The COVID-19 pandemic has exposed the ways in which global pandemic preparedness and response are under-prioritized and under-resourced. But the good news is that today’s shortfalls are finally eliciting global action.